List of Regenerative Medicine Companies in Japan - 15

aceRNA Technologies Co., Ltd. is a biotech startup established in 2018 based on RNA design technology developed in synthetic RNA biology research by Prof. Hirohide Saito at Kyoto University. We are developing "smart gene therapy” (mRNA-based and virus-base) that enables control of therapeutic transgene expression in cell-type and -state specific manner. By that, we are committed to develop new therapeutic approach, such as in vivo cell programming.

C4U is a biotechnology venture company from Osaka University, engaging in research and development of novel genome editing technology, CRISPR-Cas3. Utilizing newly invented cutting-edge genome editing technology, C4U promotes the development of new treatments for various diseases, including genetic diseases. C4U also collaborates with other companies and is working to develop platforms for applications in other industries.

Celaid Therapeutics is a Japan-based biotechnology company, which has developed a platform technology to efficiently expand hematopoietic stem cells ex vivo without choosing its origins, including bone marrow, cord blood, or peripheral blood. By using the novel technology, we are developing a cell therapy product that brings HSC transplantation to the next level and helps patients with blood disorders. Our technology has many potential applications including gene/cell therapy that utilize gene editing on HSC. Our mission is to improve QOL of patients, their families, and HSC donors all over the world.

Cellusion is committed to pursuing a patient-centric approach at our cutting-edge research and development (R&D) for diseases where regenerative medicine technologies can create a unique value proposition. We expand the possibilities of people around the world both physically and mentally.

弊社は、バイオ革命によって急速に発展し始めている再生医療分野において、体性幹細胞再生医薬品/iPSC再生医薬品の研究開発を行っているバイオベンチャーです。2015年6月には東証マザーズに上場。再生・細胞医薬品の開発・製造を世界で先駆けて取り組み、病で苦しむ患者さんに治療法を提供し希望を届けることを目標としています。 Our company is a bio venture which is doing R & D of somatic stem cell regenerating medicine / iPSC regenerating medicine in the regenerative medicine field which is rapidly developing by the bio-revolution. We were listed on TSE Mothers in June 2015. Our long-term object is to deliver hope to patients suffering from illness by providing treatment methods by pioneering the development and manufacture of regeneration and cellular medicines worldwide.

iHeart Japan​ is an venture company developing regenerative medicine products.

Integriculture Inc., a cellular agriculture platform company, develops sustainable protein, namely cell-based meat, and offers its production capability and technology to variety of clients wanting to develop products involving cell culture. Cell-based meat carries high hope as the holy grail to sustainable protein, for which $2T market is at stake. However, the production cost has been prohibitively high. Our patented “CulNet System” cultures cells 4~5 orders of magnitude less expensive to enable us to market cell-based meat at competitive prices. The system requires no externally added growth factors or serum, making it cleaner and safer compared to conventional meat, and even products by other cellular agriculture companies. The system in principle cultures any cells and produce anything produced by living things. Its astounding versatility makes it ideal for a general platform for clients wanting to produce food, cosmetics, supplements, functional ingredients, pharmaceuticals, and any other biological and agricultural products.

JCR Pharmaceutical is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. Our core values – reliability, confidence, and belief – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We continue to build upon our 49-year legacy in Japan while expanding our global footprint with trials in the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. We are leaders in developing therapies for rare conditions, including lysosomal storage disorders (LSDs). We are building on the development work we've done in Japan to expand our LSD pipeline: Our first-in-class proprietary technology, J-Brain Cargo®, enables us to develop therapies that cross the blood-brain barrier and penetrate the central nervous system (CNS). The CNS complications of diseases are often severe, resulting in developmental delays, an impact on cognition and, above all, poor prognosis, which affect patients' independence as well as the quality of life of patients and their caregivers. With J-Brain Cargo®, we seek to address the unresolved clinical challenges of LSDs and CNS-related disorders, including neurodegeneration, neuro-oncology, and neuro-inflammation conditions, by delivering the therapy to both the body and the brain. We will continuously try to create value by our unique J-Brain Cargo® technology platform toward our corporate philosophy: “contributing towards people’s healthcare through pharmaceutical products.” In addition to the in-house research activities, we think collaborative research and development work with other companies are also important. The value of our technology platform will be increased by integrating ours with other technologies and by implementing J-Brain Cargo® within other companies’ products.

Kidswell Bio Corporation (KWB), formerly known as Gene Techno Science, has been growing by leveraging our expertise in Biosimilar field in Japan. By 2024, four BS products were brought to market by our partner pharmaceutical companies as outcomes of co-developments between the companies and KWB. Besides, KWB has engaged in research and development for regenerative medicine with stem cells from human exfoliated deciduous teeth (SHED) since 2019, which targeted pediatric diseases, orphan disease and intractable disease with the aim of achieving comprehensive healthcare solutions for patients suffering from these diseases as well as for their families and caregivers. On the 1st of April 2024, the regenerative medicine business became independent as S-Quatre Corporation (SQ). KWB and SQ lead biosimilar business and regenerative medicine business　respectively, and grow together as two pillars of Kidswell Bio group. キッズウェル・バイオ株式会社(旧株式会社ジーンテクノサイエンス)はバイオシミラー医薬品事業により成長してきた。パートナー製薬企業との共同開発の結果、2024年までに4つのバイオシミラー製品を日本にて上市させている。一方で、2019年からは、乳歯由来歯髄幹細胞を用いた再生医療の研究開発に着手し、希少疾患、難病に加えて、小児疾患を重点的なターゲットと定め、患者様、及びそのご家族や介護者の方を含めた包括的なケアを目指した研究開発を行なってきた。KWBは2024年4月1日にこの再生医療事業を専門に行なう子会社である株式会社S-Quatreを設立し、現在はキッズウェル・バイオグループとしてバイオシミラーと再生医療の両事業を展開している。

This company is a spinout from Takeda Pharmaceuticals and Kyoto University, focusing on the development of induced pluripotent stem cell (iPSC) technology-based regenerative medicine.

Rege Nephro is a clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD) and small molecule for autosomal dominant polycystic kidney disease (ADPKD), and founded in 2019. There are 13 million patients with CKD in Japan, of which 340,000 are severe CKD patients forced to undergo artificial dialysis. The healthcare cost of dialysis is $12 billion, 4% of the total healthcare cost of Japan. However, there is still no curative treatment for CKD. Rege Nephro tries to treat patients suffering from CKD with cell therapy using nephron progenitor cells differentiated from iPS cells.

REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models (Alvetex) cell differentiation, and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, our labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL also offers a GMP iPSC master cell bank manufacturing service. *** REPROCELL went public on the Japan JASDAQ in June 2013. Stemgent, BioServe and Reinnervate became parts of REPROCELL in 2014. Biopta was then acquired in 2015.

Teijin is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan's first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people in 20 countries. Through our purpose of "Pioneering Solutions Togeher for a Healthy Planet". Teijin relentlessly strives to aims to be a company that supports the society of the future by protecting the global environment and addressing the needs of people and communities. Teijin posted consolidated sales of JPY 1,032.8 billion (USD 6.6 billion) and total assets of JPY 1,251.0 billion (USD 8.0 billion) in the fiscal year ending March 31, 2024.